Novogenia AG, an international healthcare company based in Munich, Germany, has announced the U.S. market launch of its new MGT Plus methylation test, expanding its product portfolio and strengthening its collaboration with U.S. partner 10X Health. The test, which analyzes 27 genes across six interconnected biological pathways, offers a more comprehensive assessment of methylation processes than commercially available tests, which typically examine only a limited number of genes.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. It plays a critical role in the processing of vitamins, neurotransmitters, and other biological molecules, influencing overall health and disease risk. By covering a broader scope of genetic markers, MGT Plus provides deeper insights into methylation-related pathways, including energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health. This expanded analysis enables more precise identification of genetic factors that may affect an individual's health, paving the way for more personalized prevention and health strategies.
According to Dr. Daniel Wallerstorfer, CEO of Novogenia AG, the launch underscores the company's commitment to making scientific innovations accessible internationally. “With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes,” he said. “The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies.” He added that the collaboration with 10X Health highlights their dedication to advancing personalized approaches to preventive health.
The introduction of MGT Plus comes at a time when the global direct-to-consumer testing market is experiencing robust growth. In 2025, the market was valued at approximately $4.7 billion and is projected to reach over $16.0 billion by 2033. The genetic testing sector is a major driver, accounting for more than 40% of the market, with North America leading the way at around 50% of global market volume in 2025. This growth is fueled by increasing consumer interest in personalized health information, prevention, and tailored health services.
For Novogenia, the U.S. launch represents a strategic move to capitalize on these trends. The company, which operates its own laboratory and partners with healthcare professionals, aims to integrate genetic insights into personalized nutrition, supplements, and cosmetics. By expanding its international product portfolio, Novogenia is positioning itself to meet the rising demand for advanced genetic testing solutions that empower individuals to take proactive control of their health.
The MGT Plus test is now available through 10X Health in the U.S., marking a significant milestone in the partnership between the two companies. As the market for personalized health continues to expand, Novogenia's innovative approach to methylation analysis could set new standards in the industry, offering consumers a more detailed understanding of their genetic makeup and its implications for long-term wellness.
